The EMA CHMP provide positive opinion on cilta-cel for RRMM

On March 24, 2022, it was announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) provide a positive opinion for granting a conditional marketing authorization for the use of ciltacabtagene autoleucel (cilta-cel) for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM). The marketing authorization is for patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy.¹

Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy, which has recently been granted approval by the U.S. Food and Drug Administration (FDA) in this patient population based on results of the CARTITUDE-1 trial. Read more about this here.